Last Updated : June 30, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | garadacimab | Hereditary angioedema (HAE) | Pending | |||
| TBC | exagamglogene autotemcel | Sickle cell disease (SCD) | Active | |||
| TBC | exagamglogene autotemcel | Transfusion-dependent β-thalassemia | Active | |||
| TBC | momelotinib | Myelofibrosis | Received | |||
| TBC | clindamycin plus benzoyl peroxide and adapalene | acne vulgaris | Active | |||
| TBC | ivosidenib | Acute myeloid leukemia (AML) | Active | |||
| TBC | pegcetacoplan | Geographic atrophy secondary to age-related macular degeneration | Pending | |||
| TBC | danicopan | Paroxysmal nocturnal hemoglobinuria (PNH) | Active | |||
| TBC | donanemab | Alzheimer disease | Pending | |||
| TBC | talquetamab | Relapsed or refractory multiple myeloma | Active | |||
| TBC | etonogestrel | Prevention of pregnancy | Withdrawn | |||
| TBC | ravulizumab | Paroxysmal nocturnal hemoglobinuria. | Withdrawn | |||
| TBC | abaloparatide | Osteoporosis, postmenopausal women | Withdrawn | |||
| TBC | tirzepatide | Diabetes mellitus, type 2 | Cancelled | |||
| TBC | halobetasol propionate and tazarotene | Psoriasis, moderate to severe plaque | Withdrawn | |||
| TBC | daprodustat | Anemia due to chronic kidney disease | Withdrawn | |||
| TBC | ferumoxytol | Iron deficiency anemia | Withdrawn | |||
| TBC | Darunavir / cobicistat | HIV infection | Withdrawn | |||
| TBC | zolbetuximab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Pending | |||
| TBD | Entrectinib | Withdrawn | ||||
| TBD | Cabozantinib | Withdrawn | ||||
| TBD | Bevacizumab | Cancelled | ||||
| TBD | Rituximab | Cancelled | ||||
| TBD | Trastuzumab | Cancelled | ||||
| Tecartus | brexucabtagene autoleucel | Mantle cell lymphoma | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : June 30, 2024